Drug intelligence / Profile preview

sotirimod

Development stage: Unknown
Lead developer: 3M
Modality: Small Molecules
Administration: Topical

Overview

Sotirimod is a small molecule immunomodulator that acts as an agonist of Toll-like receptor 7 (TLR7). It was originally developed by 3M Pharmaceuticals and later licensed to Meda for development in Europe. Sotirimod was investigated primarily for the treatment of actinic keratosis and other skin infections or disorders. Its mechanism involves stimulating the immune system via TLR7 activation, similar to imiquimod (Aldara), with reported antitumor and antiviral activity. Clinical development reached up to phase II/III trials for actinic keratosis but there are no recent reports of further progress[1][2][3][4][5].

Other names: Sotirimod [USAN:INN]UNII-X04FQM7J4MUNII-X-04FQM7J4MUNII-X 04FQM7J4MS-30594S30594S 30594

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on sotirimod.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sotirimod.

Explore the full profile